参考文献/References:
[1] Witteles RM,BokharI S,Damy T,et al. Screening for transthyretin amyloid cardiomyopathy in everyday practice[J]. JACC Heart Fail,2019,7(8):709-16.
[2] Ruberg FL,Grogan M,Hanna M,et al. Transthyretin amyloid cardiomyopathy:JACC state-of-the-art review[J]. J Am Coll Cardiol,2019,73(22):2872-2891.
[3] Cuddy S,Jerosch-Herold M,Dorbala S. Phenotyping of cardiac amyloidosis:advancing from macro to micro?[J]. Circ Cardiovasc Imaging,2020,13(5):e010785.
[4] Kittleson MM,Maurer MS,Ambardekar AV,et al. Cardiac amyloidosis:evolving diagnosis and management:a scientific statement from the American Heart Association[J]. Circulation,2020,142(1):e7-e22.
[5] Gillmore JD,Damy T,Fontana M,et al. A new staging system for cardiac transthyretin amyloidosis[J]. Eur Heart J,2018,39(30):2799-2806.
[6] Bing R,Dweck MR. Myocardial fibrosis:why image,how to image and clinical implications[J]. Heart,2019,105(23):1832-1840.
[7] Nguyen KL,Hu P,Finn JP. cardiac magnetic resonance quantification of structure-function relationships in heart failure[J]. Heart Fail Clin,2021,17(1):9-24.
[8] Martinez-Naharro A,Treibel TA,Abdel-Gadir A,et al. Magnetic resonance in transthyretin cardiac amyloidosis[J]. J Am Coll Cardiol,2017,70(4):466-477.
[9] Maurer MS,Elliott P,Comenzo R,et al. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis[J]. Circulation,2017,135(14):1357-1377.
[10] Chacko L,Martone R,Cappelli F,et al. Cardiac amyloidosis:updates in imaging[J]. Curr Cardiol Rep,2019,21(9):108.
[11] 陶逸菁,高程洁,吴昊,等. 心脏磁共振电影成像在射血分数保留心力衰竭诊治中的应用[J]. 第二军医大学学报,2017,38(10):1273-1278.
[12] Terrier B,Dechartres A,Gouya H,et al. Cardiac intravoxel incoherent motion diffusion-weighted magnetic resonance imaging with T1 mapping to assess myocardial perfusion and fibrosis in systemic sclerosis:association with cardiac events from a prospective cohort study[J]. Arthritis Rheumatol,2020,72(9):1571-1580.
[13] Bhuiyan T,Helmke S,Patel AR,et al. Pressure-volume relationships in patients with transthyretin (ATTR) cardiac amyloidosis secondary to V122I mutations and wild-type transthyretin:Transthyretin Cardiac Amyloid Study (TRACS)[J]. Circ Heart Fail,2011,4(2):121-128.
[14] Romano S,Judd RM,Kim RJ,et al. Left ventricular long-axis function assessed with cardiac cine MR imaging is an independent predictor of all-cause mortality in patients with reduced ejection fraction:a multicenter study[J]. Radiology,2018,286(2):452-460.
[15] Martinez-naharro A,Baksi AJ,Hawkins PN,et al. Diagnostic imaging of cardiac amyloidosis[J]. Nat Rev Cardiol,2020,17(7):413-426.
[16] Taylor RJ,Moody WE,Umar F,et al. Myocardial strain measurement with feature-tracking cardiovascular magnetic resonance:normal values[J]. Eur Heart J Cardiovasc Imaging,2015,16(8):871-881.
[17] Williams LK,Forero JF,Popovic ZB,et al. Patterns of CMR measured longitudinal strain and its association with late gadolinium enhancement in patients with cardiac amyloidosis and its mimics[J]. J Cardiovasc Magn Reson,2017,19(1):61.
[18] Pandey T,Alapati S,Wadhwa V,et al. Evaluation of myocardial strain in patients with amyloidosis using cardiac magnetic resonance feature tracking[J]. Curr Probl Diagn Radiol,2017,46(4):288-294.
[19] Fontana M,Pica S,Reant P,et al. Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis[J]. Circulation,2015,132(16):1570-1579.
[20] Dungu JN,Valencia O,Pinney JH,et al. CMR-based differentiation of AL and ATTR cardiac amyloidosis[J]. JACC Cardiovasc Imaging,2014,7(2):133-142.
[21] Martinez-Naharro A,Kotecha T,Norrington K,et al. Native T1 and extracellular volume in transthyretin amyloidosis[J]. JACC Cardiovasc Imaging,2019,12(5):810-819.
[22] Messroghli DR,Moon JC,Ferreira VM,et al. Clinical recommendations for cardiovascular magnetic resonance mapping of T1,T2,T2* and extracellular volume:A consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI)[J]. J Cardiovasc Magn Reson,2017,19(1):75.
[23] Baggiano A,Boldrini M,Martinez-Naharro A,et al. Noncontrast magnetic resonance for the diagnosis of cardiac amyloidosis[J]. JACC Cardiovasc Imaging,2020,13(1 Pt 1):69-80.
[24] Su MY,Hou KY,Liu MH,et al. CMR-derived ECVs vary with myocardial region and associate with the regional wall thickness[J]. Sci Rep,2020,10(1):20965.
[25] Haaf P,Garg P,Messroghli DR,et al. Cardiac T1 mapping and extracellular volume (ECV) in clinical practice:a comprehensive review[J]. J Cardiovasc Magn Reson,2016,18(1):89.
[26] Martinez-Naharro A,Abdel-Gadir A,Treibel TA,et al. CMR-verified regression of cardiac al amyloid after chemotherapy[J]. JACC Cardiovasc Imaging,2018,11(1):152-154.
[27] Wu MT,Tseng WY,Su MY,et al. Diffusion tensor magnetic resonance imaging mapping the fiber architecture remodeling in human myocardium after infarction:correlation with viability and wall motion[J]. Circulation,2006,114(10):1036-1045.
[28] Li L,Chen X,Yin G,et al. Early detection of left atrial dysfunction assessed by CMR feature tracking in hypertensive patients[J]. Eur Radiol,2020,30(2):702-711.
[29] Mekkaoui C,Jackowski MP,Kostis WJ,et al. Myocardial scar delineation using diffusion tensor magnetic resonance tractography[J]. J Am Heart Assoc,2018,7(3):e007834.
[30] Nielles-Vallespin S,Khalique Z,Ferreira PF,et al. Assessment of myocardial microstructural dynamics by in vivo diffusion tensor cardiac magnetic resonance[J]. J Am Coll Cardiol,2017,69(6):661-676.
[31] Gotschy A,von Deuster C,van Gorkum RJH,et al. Characterizing cardiac involvement in amyloidosis using cardiovascular magnetic resonance diffusion tensor imaging[J]. J Cardiovasc Magn Reson,2019,21(1):56.
[32] Khalique Z,Ferreira PF,Scott AD,et al. Diffusion tensor cardiovascular magnetic resonance in cardiac amyloidosis[J]. Circ Cardiovasc Imaging,2020,13(5):e009901.
[33] Nielles-Vallespin S,Scott A,Ferreira P,et al. Cardiac diffusion:technique and practical applications[J]. J Magn Reson Imaging,2020,52(2):348-368.
相似文献/References:
[1]刘静 彭礼清.心外膜脂肪组织定量评价的影像学进展[J].心血管病学进展,2020,(9):922.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.009]
LIU Jing,PENG Liqing.Quantitative Evaluation of Epicardial Adipose Tissue Measured by Different Imaging Methods[J].Advances in Cardiovascular Diseases,2020,(4):922.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.009]
[2]叶鹏飞 郭应坤 张怡 沈梦婷 李湘 陈林 徐婷 文凌仪.动脉粥样硬化斑块磁共振成像动物模型[J].心血管病学进展,2021,(8):730.[doi:10.16806/j.cnki.issn.1004-3934.2021.08.014]
YE Pengfei,GUO Yingkun,ZHANG Yi,et al.Animal Models for Magnetic Resonance Imaging of Atherosclerotic Plaque[J].Advances in Cardiovascular Diseases,2021,(4):730.[doi:10.16806/j.cnki.issn.1004-3934.2021.08.014]
[3]甘宏博 高电萨 左中.心脏磁共振特征追踪技术评估心脏功能的应用价值[J].心血管病学进展,2022,(4):326.[doi:10.16806/j.cnki.issn.1004-3934.2022.04.010]
GAN HongboGAO DiansaZUO Zhong?/html>.The Value of Cardiac Magnetic Resonance Feature Tracing in?valuating Cardiac Function[J].Advances in Cardiovascular Diseases,2022,(4):326.[doi:10.16806/j.cnki.issn.1004-3934.2022.04.010]
[4]陆文烨 宋梦星 吴芬 夏敏 马占龙.磁共振靶向成像检测大鼠纤维化心肌中肌腱蛋白X表达的实验研究[J].心血管病学进展,2022,(5):463.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.019]
LU Wenye,SONG Mengxing,WU Fen,et al.Experimental Study on Expression of Tenascin-X in Fibrotic Myocardium of Rat by Magnatic Resonance Targeted Imaging[J].Advances in Cardiovascular Diseases,2022,(4):463.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.019]
[5]林志勇 邱建星.影像学在肾血管性高血压评估中的进展[J].心血管病学进展,2024,(3):201.[doi:10.16806/j.cnki.issn.1004-3934.2024.03.003]
LIN Zhiyong,QIU Jianxing.Imaging Assessment of Renovascular Hypertension[J].Advances in Cardiovascular Diseases,2024,(4):201.[doi:10.16806/j.cnki.issn.1004-3934.2024.03.003]
[6]龙颉婧 邱悦 马春燕 陈昕.主动脉瓣狭窄合并心脏淀粉样变的研究进展[J].心血管病学进展,2024,(8):697.[doi:10.16806/j.cnki.issn.1004-3934.2024.08.006]
LONG Xiejing,QIU Yue,MA Chunyan,et al.Concomitant Aortic Stenosis and Cardiac Amyloidosis[J].Advances in Cardiovascular Diseases,2024,(4):697.[doi:10.16806/j.cnki.issn.1004-3934.2024.08.006]
[7]王银秋 彭礼清.心脏磁共振在轻链型淀粉样变预后评估及风险分层中的研究进展[J].心血管病学进展,2024,(8):702.[doi:10.16806/j.cnki.issn.1004-3934.2024.08.007]
WANG Yinqiu,PENG Liqing.Application of Cardiac Magnetic Resonance in Prognosis and Risk Stratification in Light-Chain Amyloidosis[J].Advances in Cardiovascular Diseases,2024,(4):702.[doi:10.16806/j.cnki.issn.1004-3934.2024.08.007]